• Media type: E-Article
  • Title: Ergot mesylates for alzheimer's disease: A year‐long double‐blind trial of 3 mg vs 12 mg daily
  • Contributor: Jenike, Michael A.; Albert, Marilyn; Baer, Lee; Gunther, Jeanette; Corvino, Christine
  • imprint: Wiley, 1990
  • Published in: International Journal of Geriatric Psychiatry
  • Language: English
  • DOI: 10.1002/gps.930050605
  • ISSN: 0885-6230; 1099-1166
  • Keywords: Psychiatry and Mental health ; Geriatrics and Gerontology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Of 25 patients who entered a year‐long double‐blind comparison study of high (12 mg/day) <jats:italic>versus</jats:italic> low (3 mg/day) dosages of ergot mesylates (Hydergine), 17 completed the full year of study and no patients suffered problematic side‐effects. On a number of complex tests of memory function, there was no difference between the patients receiving low‐dose <jats:italic>versus</jats:italic> high‐dose Hydergine. There were also no significant between‐group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.</jats:p>